Back

Immune-mediated Engagement of T Regulatory Cells with Tumor Cells Results in Trogocytosis and Tumor Cell Killing.

Erbe, A. K.; Feils, A. S.; Gao, A.; VandenHeuvel, S.; Boyenga, S.; Hampton, A.; Heck, M.; Zaborek, J.; Spiegelman, D.; Tsarovsky, N.; Hoefges, A.; Pieper, A. A.; Carlson, P. M.; Felder, M.; Patel, R. B.; Gillies, S. D.; Heaton, A.; Morris, Z.; Dinh, H. Q.; Rakhmilevich, A. L.; Sondel, P. M.

2025-12-15 cancer biology
10.64898/2025.12.11.693807 bioRxiv
Show abstract

Despite advances in treatment, >50% of patients with advanced melanoma are unresponsive to current therapies. Using the B78-D14 melanoma model (GD2+/MHC-I-/MHC-II+), we can cure mice with a regimen that includes radiation therapy (RT) in combination with immunocytokine (IC; anti-GD2 monoclonal antibody linked to IL-2) while establishing immunological memory. We interrogated the role of T cells in the antitumor and memory responses following RT+IC. We show a requirement for CD4, but not CD8 T cells, to achieve both the initial and memory responses. Upon IC-induced cell-cell contact, subsets of CD4 T cells, including Foxp3 T regulatory cells, trogocytose GD2 from tumor cells, acquire cytotoxic granules, and kill tumor cells. These results were confirmed using human tumor cell lines. These findings reveal that CD4 T regulatory cells, upon immunologically-induced binding to tumor cells, can trogocytose tumor antigens and directly kill tumor cells, redefining their potential role in antitumor immunity.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.